Bedaquiline
Brand names: Sirturo · Active ingredient: Bedaquiline Fumarate
In short: SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid
What is Bedaquiline used for?
SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (2 years and older and weighing at least 8 kg) with pulmonary tuberculosis (TB) due to
Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.
Limitations of Use
Do not use SIRTURO for the treatment of:
Latent infection due to
Mycobacterium tuberculosis (
M. tuberculosis)
Drug-sensitive pulmonary TB
Extra-pulmonary TB
Infections caused by non-tuberculous mycobacteria
âš Boxed warning (FDA's strongest warning)
QTc prolongation can occur with SIRTURO. Use with drugs that prolong the QTc interval may cause additive QTc prolongation. Monitor ECGs. Discontinue SIRTURO if significant ventricular arrhythmia or QTc interval greater than 500 ms develops
.
Bedaquiline dosage
Administer SIRTURO by directly observed therapy (DOT).
Only use SIRTURO in combination with at least three other drugs to which the patient's TB isolate has been shown to be susceptible in vitro. If in vitro testing results are unavailable, SIRTURO treatment may be initiated in combination with at least four other drugs to which the patient's TB isolate is likely to be susceptible. Refer to the prescribing information of the drugs used in combination with SIRTURO for further information.
SIRTURO (20 mg and 100 mg) must be taken with food.
SIRTURO 20 mg are functionally scored tablets which can be split at the scored lines into two equal halves of 10 mg each to provide doses less than 20 mg
.
As an alternative method of administration, SIRTURO 20 mg tablets can be dispersed in water and administered or dispersed in water and further mixed with a beverage or soft food, or crushed and mixed with soft food, or administered through a feeding tube
.
Emphasize the need for compliance with the full course of therapy.
Prior to treatment with SIRTURO, obtain the following:
Susceptibility information for the background regimen against
M. tuberculosis isolate if possible
ECG
Serum potassium, calcium, and magnesium concentrations
Liver enzymes
The recommended dosage of SIRTURO in adult patients is:
Dosage Recommendation
Weeks 1 and 2 | Weeks 3 to 24
At least 48 hours between doses
400 mg (4 of the 100 mg tablets OR 20 of the 20 mg tablets) orally
once daily | 200 mg (2 of the 100 mg tablets OR 10 of the 20 mg tablets) orally
three times per week
Recommended dosage in pediatric patients is described in Table 2 below
.
Administer SIRTURO tablets with food. The total duration of treatment with SIRTURO in adults is 24 weeks. When treatment with SIRTURO is considered necessary beyond 24 weeks, treatment may be continued at a dose of 200 mg three times per week
. …
How to take Bedaquiline — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Medication Guide).
Serious Adverse Reactions
Advise patients that the following serious side effects can occur with SIRTURO: heart rhythm abnormalities, death and/or hepatitis. In addition, advise patients about other potential side effects: nausea, vomiting, joint pain, increased transaminases, dizziness, headache, myalgia, diarrhea, increased blood amylase, hemoptysis, chest pain, anorexia, rash, and/or abdominal pain. Additional testing may be needed to monitor or reduce the likelihood of adverse effects.
Compliance with Treatment
Advise patients to take SIRTURO in combination with other antimycobacterial drugs as prescribed. Emphasize compliance with the full course of therapy. Advise patients that skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the treatment and (2) increase the likelihood that their mycobacterium may develop resistance and the disease will not be treatable by SIRTURO or other antimycobacterial drugs in the future. …
Warnings & precautions
Do not take this medicine if: None.
SIRTURO prolongs the QTc interval
. Use with drugs that prolong the QTc interval may cause additive QTc prolongation
. In Study 4, where SIRTURO was administered with the QTc prolonging drugs clofazimine and levofloxacin, 5% of patients in the 40-week SIRTURO treatment group experienced a QTc ≥500 ms and 43% of patients experienced an increase in QTc ≥60 ms over baseline. Of the clofazimine- and levofloxacin-treated patients in the 40-week control arm, 7% of patients experienced a QTc ≥500 ms and 39% experienced an increase in QTc ≥60 ms over baseline.
Obtain an ECG before initiation of treatment, 2 weeks after initiation, during treatment, as clinically indicated and at the expected time of maximum increase in the QTc interval of the concomitantly administered QTc prolonging drugs (as applicable). Obtain electrolytes at baseline and during treatment and correct electrolytes as clinically indicated.
The following may increase the risk for QTc prolongation when patients are taking SIRTURO:
use with other QTc prolonging drugs
a history of Torsade de Pointes
a history of congenital long QTc syndrome
a history of or ongoing hypothyroidism
a history of or ongoing bradyarrhythmias
a history of uncompensated heart failure
serum calcium, magnesium, or potassium levels below the lower limits of normal
Discontinue SIRTURO if the patient develops:
Clinically significant ventricular arrhythmia
A QTc interval of greater than 500 ms (confirmed by repeat ECG)
If syncope occurs, obtain an ECG to detect QTc prolongation.
An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial in adults (Study 1; based on the 120 week visit window). One death occurred during the 24 weeks of administration of SIRTURO. The imbalance in deaths is unexplained. …
Bedaquiline side effects
The following serious adverse reactions are discussed elsewhere in the labeling:
QTc Prolongation
Mortality Imbalance in Clinical Trials
Hepatotoxicity
Drug Interactions
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. Refer to the prescribing information of the drugs used in combination with SIRTURO for their respective adverse reactions.
Clinical Studies Experience in Adults
Adverse reactions for SIRTURO were identified from safety data from 335 patients who received SIRTURO for eight weeks (Study 2) and 24 weeks (Studies 1 and 3), and 354 patients who received SIRTURO for 40 weeks or 28 weeks (Study 4). In these studies, patients received SIRTURO in combination with other antimycobacterial drugs.
Studies 1 and 2 were randomized, double-blind, placebo-controlled trials in newly diagnosed patients with pulmonary TB due to
M. tuberculosis resistant to at least rifampin and isoniazid. Study 3 was an open-label, noncomparative study with SIRTURO administered as part of an individualized treatment regimen in previously treated patients with pulmonary TB due to
M. tuberculosis resistant to at least rifampin and isoniazid, including patients resistant to second-line injectables and/or fluroquinolones. …
Drug interactions
Strong and Moderate CYP3A4 Inducers
Coadministration of SIRTURO with moderate or strong CYP3A4 inducers may decrease systemic exposure of bedaquiline. Avoid coadministration of SIRTURO with strong or moderate CYP3A4 inducers
.
CYP3A4 Inhibitors
Coadministration of SIRTURO with CYP3A4 inhibitors increases the systemic exposure of bedaquiline which may increase the risk of adverse reactions. Closely monitor patient safety (e.g., liver function) when SIRTURO is coadministered with CYP3A4 inhibitors. No dose adjustment of SIRTURO is needed when coadministered with CYP3A4 inhibitors
.
No dose adjustment of isoniazid or pyrazinamide is required during coadministration with SIRTURO.
In a placebo-controlled clinical trial in adult patients, no major impact of coadministration of SIRTURO on the pharmacokinetics of ethambutol, kanamycin, pyrazinamide, ofloxacin or cycloserine was observed.
In clinical trials of adult patients, additional QTc interval prolongation was observed during combination treatment with SIRTURO and other QTc prolonging drugs. …
About this medicine
SIRTURO
® contains bedaquiline fumarate, a diarylquinoline antimycobacterial drug for oral administration. Each SIRTURO 20 mg tablet contains 20 mg of bedaquiline (equivalent to 24.18 mg of bedaquiline fumarate). Each SIRTURO 100 mg tablet contains 100 mg of bedaquiline (equivalent to 120.89 mg of bedaquiline fumarate).
Bedaquiline fumarate is a white to almost white powder and is practically insoluble in aqueous media. The chemical name of bedaquiline fumarate is (1
R, 2
S)-1-(6-bromo-2-methoxy-3-quinolinyl)-4-(dimethylamino)-2-(1-naphthalenyl)-1-phenyl-2-butanol compound with fumaric acid (1:1). It has a molecular formula of C
32H
31BrN
2O
2∙C
4H
4O
4 and a molecular weight of 671.58 (555.50 + 116.07). The molecular structure of bedaquiline fumarate is the following:
SIRTURO 20 mg tablet contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose 2910 5 mPa.s, polysorbate 20, purified water (removed during processing), silicified microcrystalline cellulose and sodium stearyl fumarate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1534c9ae-4948-4cf4-9f66-222a99db6d0e. Read the full official label on DailyMed.
Related medicines
Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin